

Doc code :IDS

Doc description: Information Disclosure Statement (IDS) Filed

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08a (10-08)

Approved for use through 11/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10597930
Filing Date		2006-12-04
First Named Inventor	David Platt	
Art Unit	1623	
Examiner Name	Layla D. Bland	
Attorney Docket Number	089918-021302	

**U.S.PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3983140		1976-09-28	Endo et al.	
	2	4231938		1980-11-04	Monaghan et al.	
	3	4346227		1982-08-24	Terahara et al.	
	4	4444784		1984-04-24	Hoffman et al.	
	5	4450171		1984-05-22	Hoffman et al.	
	6	4681893		1987-07-21	Roth	
	7	4739073		1988-04-19	Kathawala	
	8	4804770		1989-02-14	Karanewsky	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10597930
Filing Date		2006-12-04
First Named Inventor	David Platt	
Art Unit	1623	
Examiner Name	Layla D. Bland	
Attorney Docket Number	089918-021302	

9	4946830		1990-08-07	Pulverer et al.	
10	4970150		1990-11-13	Yaku et al.	
11	5015632		1991-05-14	Nelson, John D.	
12	5082859		1992-01-21	Festal et al.	
13	5102888		1992-04-07	Fujikawa et al.	
14	5118673		1992-06-02	Carpenter et al.	
15	5260440		1993-11-09	Hirai et al.	
16	5273995		1993-12-28	Roth	
17	5441943		1995-08-15	Mcanalley et al.	
18	5502199		1996-03-26	Angerbauer et al.	
19	5569483		1996-10-29	Timonen et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

	20	5620961		1997-04-15	Markovic et al.	
	21	5626856		1997-05-06	Berndt	
	22	5773425		1998-06-30	Mcanalley et al.	
	23	5786342		1998-07-28	Carpenter et al.	
	24	5834442		1998-11-10	Raz et al.	
	25	5861142		1999-01-19	Schick	
	26	5869289		1999-02-09	Hawkins et al.	
	27	5891861		1999-04-06	Platt, David	
	28	5895784		1999-04-20	Raz et al.	
	29	5908761		1999-06-01	Zick	
	30	5995100			Bosslet et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10597930
Filing Date		2006-12-04
First Named Inventor	David Platt	
Art Unit	1623	
Examiner Name	Layla D. Bland	
Attorney Docket Number	089918-021302	

	31	6190657		2001-02-20	Pawelek et al.	
	32	6329422		2001-12-11	Fischer et al.	
	33	6413494		2002-07-02	Lee et al.	
	34	6417173		2002-07-09	Roufa et al.	
	35	6550807		2002-12-31	Platt et al.	
	36	6642205		2003-11-04	Klyosov et al.	
	37	6645946		2003-11-11	Klyosov et al.	
	38	6652856		2003-11-23	Gotwals et al.	
	39	6756362		2004-06-29	Roufa et al.	
	40	6756401		2004-06-29	Day et al.	
	41	6787521		2004-09-07	Culler et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

42	6844354	2005-01-18	lizuka, et al.
43	6893637	2005-05-17	Gilbertson

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20010026807		2001-10-04	Watts	
	2	20010036483		2001-11-01	Scott et al.	
	3	20020044967		2002-04-18	Yamashita et al.	
	4	20020058061		2002-05-16	Midha et al.	
	5	20020068077		2002-06-06	Klyosov et al.	
	6	20020107222		2002-08-08	Platt	
	7	20030013681		2003-01-16	Chang et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2i</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	2029220	GB		1980-03-19	Otsuka Pharmaceutical		<input type="checkbox"/>
	2	84/04041	WO		1984-10-25	Friend et al.		<input type="checkbox"/>
	3	0382210	EP		1990-08-16	Unitika, Ltd.		<input type="checkbox"/>
	4	04288017	JP		1992-10-13	Pias KK		<input type="checkbox"/>
	5	93/08810 A1	WO		1993-15-13	Carrington Laboratories, Inc.		<input type="checkbox"/>
	6	05124956	JP		1993-05-21	Snow Brand Milk Prod Co Ltd		<input type="checkbox"/>
	7	0595133 A	EP		1994-05-04	Behringwerke AG		<input type="checkbox"/>
	8	96/19243 A	WO		1996-06-27	Co. Enzyme Technology Ltd.		<input type="checkbox"/>
	9	0721784	EP		1996-07-16	KANEGAFUCHI CHEMICAL IND		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

10	19524515 A	DE		1997-01-09	Deutsches Krebsforsch		<input type="checkbox"/>
11	2004/024183	WO		2004-03-01	Boving et al.		<input type="checkbox"/>
12	2006/017417	WO		2006-02-16	Pro-Pharmaceuticals, Inc.		<input type="checkbox"/>
13	WO 00/07624	WO		2000-02-17	Teijin Limited		<input type="checkbox"/>
14	WO 00/62076	WO		2000-10-19	Hsu, Daniel K.		<input type="checkbox"/>
15	WO 02/057284	WO		2002-07-25	Nilsson et al.		<input type="checkbox"/>
16	WO 02/076474	WO		2002-10-03	Pro-Pharmaceuticals, Inc.		<input type="checkbox"/>
17	WO 02/26262	WO		2002-04-04	Pro-Pharmaceuticals, Inc		<input type="checkbox"/>
18	WO 03/000118	WO		2002-06-21	Glycogenesys, Inc.		<input type="checkbox"/>
19	EP 0 888 776	EP		1999-07-01	Takara Shuzo Co. Ltd.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	PALOMINO, E., "Carbohydrate Handles as Natural Resources in Drug Delivery", Advanced Drug Delivery Reviews, Amsterdam, NL, vol. 13, 1994, pages 311-323	<input type="checkbox"/>
	2	OUCHI et al., "Synthesis and Cytotoxic Activity of Oxidized Galactomannan/ADR Conjugate", JMS Pure Applied Chemistry, 1997, A34(6), pages 975-989	<input type="checkbox"/>
	3	KATZUNG, Betran, Basic and Clinical Pharmacology, 1998, 7th Edition, Appleton & Lange, pages 881-912	<input type="checkbox"/>
	4	MEY A. et al., "The Animal Lectin Galectin-3 Interacts with Bacterial Lipopolysaccharides Via Two Independent Sites", The Journal of Immunology, 1996, Vol. 156, pages 1572-1577	<input type="checkbox"/>
	5	PAN, Z.K. et al., "A Recombinant Listerin Monocytogenes Vaccine Expressing a Model Tumour Antigen Protects Mice Against Lethal Cell Challenges and Causes Regression of Established Tumours", Nat. Med., , 1995, Vol. 1, No. 5, pages 471-477	<input type="checkbox"/>
	6	PLATT, D. et al, "Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus Pectin", Journal of National Cancer Institute, 1992, Vol. 84, No. 6, pages 438-442	<input type="checkbox"/>
	7	KLYSOV, A.A. et al, "Preclinical Studies of Anticancer Efficacy of 5-Fluorouracil When Coadministered with the 1,4-beta-D-Galactomannan", Preclinica., September/October 2003, vol. 1, No. 4, pages 175-183	<input type="checkbox"/>
	8	PLATT, D. et al, "Davanat-A Modified Branched Galactomannan Enhances Chemotherapeutics: Reflections on Manufacturing, Pre-Clinical Studies and Clinical Trials", Abstract No. 1 of papers, 227th ACS National Meeting, Anaheim, CA, Publisher: American Chemical Society, Washington, D.C., March 28-April 1, 2004	<input type="checkbox"/>
	9	HETZEL et al, "Different Effects of Growth Factors on Proliferation and Matrix Productions of Normal and Fibrotic Human Lung Fibroblasts", Lung, 2005, 183, pages 225-237	<input type="checkbox"/>
	10	LOU et al., Pharmaceutical Research, 2002, Vol. 19, pages 396-402	<input type="checkbox"/>



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

11	SEO et al., "Preparation of Multifunctional Low Molecular Weight Chitosan and Its Application in Cosmetics", SOFW-Journal, 128, January 9, 2002, pages 46-51	<input type="checkbox"/>
12	International Search Report Mailed in December 14, 2005 in connection with PCT/US2005/004430	<input type="checkbox"/>
13	The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merck Research Laboratories, pages 981-995	<input type="checkbox"/>
14	ODA, "Anti-Tumor Activity of Xanthan Gum" Yakuri to Chiryo, 1985, Vol. 13, NO. 10, pages 5743-5750	<input type="checkbox"/>
15	VAN DER BOONGARD et al., "Successful Rescue with Leucovorin and Thymidine in a Patient with High-Dose Methotrexate Induced Acute Renal Failure", Cancer Chemotherapy and Pharmacology, 2001, Vol. 47, pages 537-540	<input type="checkbox"/>
16	JAKOBSEN et al., "Dose-Effect Relationship of 5-Fluorouracil in the Treatment of Advanced Colorectal Cancer", Acta Oncologica, 2002, Vol. 41, pages 525-531	<input type="checkbox"/>
17	2006 Chemical Abstracts Catalog, published 2005 by Chemical Abstracts Service, page 52	<input type="checkbox"/>
18	Avery' Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd Edition, 1987, Edited by Trevor M. Speight, Chapter VIII, pages 255-282	<input type="checkbox"/>
19	International Search Report Mailed in April 13, 2005 in connection with PCT/US2004/028883	<input type="checkbox"/>
20	International Search Report and Written Opinion Mailed in August 8, 2006 in connection with PCT/US05/27187	<input type="checkbox"/>
21	OOSTERVELD et al, "Characterization of Arabinose and Ferulic Acid Rich Pectic Polysaccharides and Hemicelluloses from Sugar Beef Pulp", Carbohydrate Research, 200, 328, pages 185-197	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

22	"Synthesis and Cytotoxic Activity of Oxidized Galactomannan/ADR Conjugate, J.M.S. Pure Applied Chemistry, 1997, A34(6), pages 975-989	<input type="checkbox"/>
23	LOPEZ E, Del Pozo V, Miguel T, Sastre B, Seoane C, Civantos E, Llanes E, Baeza ML, Palomino P, Cardaba B, Gallardo S, Manzarbeitia F, Zubeldia JM, Lahoz C. Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model. J Immunol. 2006 Feb 1;176 (3): 1943-50.	<input type="checkbox"/>
24	FITZNER B, Walzel H, Sparmann G, Emmrich J, Liebe S, Jaster R. Galectin-1 is an inducer of pancreatic stellate cell activation. Cell Signal. 2005 Oct;17(10):1240-7. Epub 2005 Jan 21.	<input type="checkbox"/>
25	MAEDA N, Kawada N, Seki S, Arakawa T, Ikeda K, Iwao H, Okuyama H, Hirabayashi J, Kasai K, Yoshizato K. Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem. 2003 May 23;278(21):18938-44. Epub 2003 Mar 19.	<input type="checkbox"/>
26	YAMAZAKI K, Kawai A, Kawaguchi M, Hibino Y, Li F, Sasahara M, Tsukada K, Hiraga K. Simultaneous induction of galectin-3 phosphorylated on tyrosine residue, p21(WAF1/Cip1/Sd1), and the proliferating cell nuclear antigen at a distinctive period of repair of hepatocytes injured by CC14. Biochem Biophys Res Commun. 2001 Feb 2;280 (4):1077-84	<input type="checkbox"/>
27	WANG L, Friess H, Zhu Z, Frigeri L, Zimmermann A, Korc M, Berberat PO, Buchler MW. Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest. 2000 Aug;80(8):1233-41	<input type="checkbox"/>
28	KASPER M, Hughes RC. Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. J Pathol. 1996 Jul;179(3):309-16	<input type="checkbox"/>
29	WERT, Susan, Mitsuhiro Yoshida, Ann Marie LeVine, Machiko Ikegami, Tracy Jones. Gary F. Ross, James H. Fisher, Thomas R. Korfhagen, and Jeffrey A. Whitsett, Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene- inactivated mice. PNAS, May 2000; 97: 5972 - 5977	<input type="checkbox"/>
30	BROWN, Michael, et al., A Receptor-Mediated Pathway for Cholesterol Homeostasis. Nobel Lecture, December 9, 1985	<input type="checkbox"/>
31	ENDO A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Research, 33, 1992, 1569-1582	<input type="checkbox"/>
32	ENDO A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. J. Med. Chem., 28, No. 4, 401-405, 1985.	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

33	ENDO A., Kuroda M., and Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites, having hypocholesterolemic activity. FEBS Letters, 72, 323-326, 1976.	<input type="checkbox"/>
34	HOLGATE G.A., Ward W.H.J., and McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem. Soc. Transactions, 31, Part 3, 528-531, 2003.	<input type="checkbox"/>
35	ENDO A., Kuroda M, and Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterologenesis produced by Penicillium citrinum. J. Antibiot. (Japan), 29, 1346-1348, 1976.	<input type="checkbox"/>
36	HMG-CoA Reductase Inhibitors. General Monograph, Canadian Pharmacists Association, 2002.	<input type="checkbox"/>
37	WEBER C., Erl W., Weber K.S.C., and Weber P.C. HMG-CoA reductase inhibitors decrease CD11 b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol., 30, 1212-1217, 1997.	<input type="checkbox"/>
38	DESAGER J.P., Normans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinetics, 31, 348-371, 1996.	<input type="checkbox"/>
39	BELLOSTA S., Via D., Canavesi M., Pfister P., Fumagalli R., and Paoletti R. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol., 18, 1671-1678, 1998.	<input type="checkbox"/>
40	AKIRA K., Amano M., Okajima F., Hashimoto T., and Oikawa S. Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits. Biol. Pharm. Bull. 29, No. 1, 75-81, 2006.	<input type="checkbox"/>
41	BERGENHEIM, A.T. et al. "Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans." Br. J. Cancer 67, 358-361 (1993).	<input type="checkbox"/>
42	BERNICK C., Katz R., Smith N.L., Rapp S., Bhadelia R., Carlson M., Kuller L. Statins and cognitive function in the elderly. Neurology, 65, 1388-1394, 2005.	<input type="checkbox"/>
43	MASSE I., Bordet R., Deplanque D., Al Khedr A., Richard F., Libersa C., and Pasquier F. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J. Neurology, Neurosurgery, and Psychiatry. 76, 1624-1629, 2005.	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

44	MIIDA T., Takahashi A., Tanabe, N., Ikeuchi, T. Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression? Current Opinion in Lipidology. 16, No. 6, 619-623, 2005.	<input type="checkbox"/>
45	BARLOGIE, B. et al., "Etoposide, Dexamethasone, Cytarabine, and Cisplatin in Vincristine, Doxorubicin, and Dexamethasone-Refractory Myeloma", Journal of Clinical Oncology, Vol. 7, No 10 (1989).	<input type="checkbox"/>
46	BELKA, C. et al. "Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL." Oncogene 20, 2190-2196 (2001).	<input type="checkbox"/>
47	BIANCO, C. et al. "Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor." Clin. Cancer Res. 8, 3250-3258 (Oct. 2002).	<input type="checkbox"/>
48	BONAVIDA, B. et al. "Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (Review)." Int. J. Oncol. 15, 793-802 (Oct. 1999).	<input type="checkbox"/>
49	CHAUHAN et al., "A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells." Cancer Res, 65: (18), (2005)	<input type="checkbox"/>
50	CHRISTODOULOU et al. "Anti-proliferate activity and mechanism of action of titanocene dichloride." Br. J. Cancer 77 (12), 2088-2097 (1998).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).


☒ See attached certification statement.

☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.


Signature		Date (YYYY-MM-DD)	2009-03-12
Name/Print	Barry Schindler	Registration Number	32,938

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

**U.S. PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2i</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

1	KILPATRICK, D. C. "Animal Lectins: a historical introduction and overview." Biochim. et Biophys. Acta 1572, 187-197 (2002).	<input type="checkbox"/>
2	KIM, Hyeong-Reh Choi et al., "Cell Cycle Arrest and Inhibition of Anoikis by Galectin-3 in Human Breast Epithelial Cells," Cancer Research 59:4148-4154 (1999)	<input type="checkbox"/>
3	KIM, R. et al. "A pitfall in the survival benefit of adjustment chemotherapy for node and hormone receptor-positive patients with breast cancer: The paradoxical role of Bcl-2 oncoprotein (Review)." Int. J. Oncol. 19, 1075-1080 (2001).	<input type="checkbox"/>
4	KLASS, R. J. et al. "Eradication of Human Non Hodgkin's Lymphoma in SCID Mice by BCL 2 Antisense Oligonucleotides Combine with Low-Dose Cyclophosphamide." Clin. Cancer Res. 6, 2492-2500 (June 2000).	<input type="checkbox"/>
5	LEFFLER, H. et al. "Specificity of Binding of Three Soluble Rat Lung Lectins to Substituted and Unsubstituted Mammalian B Galactosides." J. Biol. Chem. 261(22), 10119-10126 (5 Aug. 1986).	<input type="checkbox"/>
6	LIM, Y. et al. "Identification of autoantibodies associated with systemic lupus erythematosus. Biochem. Biophys. Res. Comm. 295, 119-124 (2002).	<input type="checkbox"/>
7	LIN, H.M. et al., "Galectin-3 Mediates Genistein-induced G2/M Arrest and Inhibits Apoptosis," Carcinogenesis 21 (11):1941-1945 (2000)	<input type="checkbox"/>
8	LINEHAN, W. M. "Inhibition of Prostate Cancer Metastasis: a Critical Challenge Ahead. J. Nat. Cancer Inst. 87(5), 331-332 (1 March 1995).	<input type="checkbox"/>
9	LIU, F.-T. et al. "Intracellular functions of galectins." Biochim et Biophys Acta 1572, 263-273 (2002).	<input type="checkbox"/>
10	LOPES DE MENEZES, D. E. et al. "Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin." Clin. Cancer Res. 6, 2891-2902 (July 2002).	<input type="checkbox"/>
11	LOTZ, M. M. et al. "Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma." PNAS 90, 3466-3470 (1993).	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

12	MAJLESSIPOUR, F. "The Combination Regimen of Idarubicin and Taxotere is Effective Against Human Drug-resistant Leukemic Cell Lines." Anticancer Res. 22, 1361-1368 (2002).	<input type="checkbox"/>
13	MATARRESE P., et al., (Abstract) "Galectin-3 Overexpression Protects from Apoptosis by Improving Cell Adhesion Properties," Int. Cancer 85(4):545-554 (2000)	<input type="checkbox"/>
14	MATARRESE, P., et al. "Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis." FEBS Letters 473, 311-315 (2000).	<input type="checkbox"/>
15	MAZUREK et al., "Phosphorylation of the B-Galactoside-binding Protein Galectin-3 Modulates Binding to its Ligands," The Journal of Biological Chemistry 275(46):36311-36315 (2000)	<input type="checkbox"/>
16	MEY, A. et al. "Expression of the galactose binding protein Mac-2 by human melanoma cell- lines." Cancer Letters 81, 155-163 (1994).	<input type="checkbox"/>
17	NAKAMURA, M. et al. "Involvement of galectin-3 expression in colorectal cancer progression and metastasis." Int. J. Oncol. 15, 143-148 (1999).	<input type="checkbox"/>
18	Novocastra Laboratories, Ltd. "Galectin-3: mouse monoclonal antibody NCL-GAL3."	<input type="checkbox"/>
19	OHANNESIAN, D. W. et al. "Carcinoembryonic Antigen and Other Glycoconjugates Act as Ligands for Galectin-3 in Human Colon Carcinoma Cells." Cancer Res. 55, 2191-2199 (15 May 1995).	<input type="checkbox"/>
20	Oncolink: Lilly Oncology Treatment Options. <a href="http://www.oncolink.com/treatment/section.cfm">www.oncolink.com/treatment/section.cfm</a> retrieved on 2/12/2003.	<input type="checkbox"/>
21	ORLANDI, F. et al. "Galectin 3 Is a Presurgical Marker of Human Thyroid Carcinoma." Cancer Res. 58, 3015-3020 (15 July 1998).	<input type="checkbox"/>
22	PERILLO, N. L. "Galectins: versatile modulators of cell adhesion, cell proliferation, and cell (1998).	<input type="checkbox"/>



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

23	PIENTA, K.J. et al. "Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin." J. Nat. Cancer Inst. 87(5), 348-353 (1 March 1995).	<input type="checkbox"/>
24	PUGLIESE, G. "The Diabetic Milieu Modulates the Advanced Glycation End Product Receptor Complexes in the Mesangium by Inducing or Upregulating Galectin-3 Expression." Diabetes 49, 1249-1257 (July 2000).	<input type="checkbox"/>
25	RABINOVICH, G.A. "Role of galectins in inflammatory and immunomodulatory processes." Biochim. Biophys. Acta 1572, 274-284 (2002).	<input type="checkbox"/>
26	RABINOVICH, G.A. et al. "Recombinant Galectin-1 and Its Genetic Delivery Suppress Collagen- induced Arthritis via T Cell Apoptosis." J. Exp. Med. 190(3), 385-397 (2 Aug. 1999).	<input type="checkbox"/>
27	RABINOVICH, G.A. et al. "The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression." Cancer Immunol. Immunother. 50, 597-(2002).	<input type="checkbox"/>
28	RABINOVICH, G.A. et al., "Galectins and Their Ligands: Amplifiers, Silencers or Tuners of the Inflammatory Response?" Trends in Immunology 23(6):313-320 (2002)	<input type="checkbox"/>
29	RAYNAUD, F. I. "Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice." J. Pharmacol Exp. Therapeutics 281(1), 420-427 (1997).	<input type="checkbox"/>
30	RUDIN, C. M. et al. "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small cell lung cancer." Ann. Oncol. 13, 539-545 (2002).	<input type="checkbox"/>
31	RUITER, G.A. et al. "Alkyl-Lysophospholipids as Anticancer Agents and Enhancers of Radiation-Induced Apoptosis." Int. J. Radiation Oncol. Biol. Phys. 49(2), 415-419 (2001).	<input type="checkbox"/>
32	SANO, H. et al. "Human Galectin-3 Is a Novel Chemoattractant for Monocytes and Macrophages." J. Immunol. 165, 2156-2164 (2000).	<input type="checkbox"/>
33	SAUER, G. et al. "New Molecular Targets of Breast Cancer Therapy." Strahlenther. Onkol. 178(3), 123-133 (2002).	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

34	SHIH, C. et al. "Cryptophycins: A Novel Class of Potent Antimitotic Antitumor Depsipeptides." Curr. Pharm. Des. 7, 1259-1276 (2001).	<input type="checkbox"/>
35	SÖRME, P. et al. "Low Micromolar Inhibitors of Galectin-3 Based on 3-Derivatization of N-Acetylactosamine." ChemBioChem 3, 183-189 (2002).	<input type="checkbox"/>
36	TAKAHASHI, T. et al. "Mechanisms of the apoptotic activity of CI-F-araA in a human T-ALL cell line, CCRF-CEM." Cancer Chemother Pharmacol. 50, 193-201 (2002).	<input type="checkbox"/>
37	TENTORI, L. et al. "Role of Wild-Type p 53 on the Antineoplastic Activity of Temozolomide Alone or Combined with Inhibitors of Poly(ADP-Ribose) Polymerase." J. Pharmacol. Exp. Therapeutics 285(2), 884-893 (1998).	<input type="checkbox"/>
38	TORTORA, G. et al. "Combined Blockade of Protein Kinase A and Bcl-2 by Antisense Strategy Induces Apoptosis and Inhibits Tumor Growth and Angiogenesis." Clin. Cancer Res. 7, 2537-2544 (Aug. 2001).	<input type="checkbox"/>
39	TORTORA, G. et al. "Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy." Ann. N.Y. Acad. Sci. 968, 139-147 (2002).	<input type="checkbox"/>
40	TU, S.-M. et al. "Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells." Cancer Letters 93, 147-155 (1995).	<input type="checkbox"/>
41	USUDA, J. et al. "Increased Cytotoxic Effects of Photodynamic Therapy in IL-6 Gene Transfected Cells via Enhanced Apoptosis." Int. J. Cancer 93, 475-480 (2001).	<input type="checkbox"/>
42	VIVAT-HANNAH, V. et al. "Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel)." Cancer Res. 61(24), 8703-8711 (15 Dec. 2001).	<input type="checkbox"/>
43	Webster's New World Dictionary, 3rd. ed., Simon & Schuster (New York, 1988) page 433.	<input type="checkbox"/>
44	XIA, F. "The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer." Semin. Radiat. Oncol. 12(4), 296-304 (2002).	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

45	XU, X.-C. et al. "Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms." Int. J. Oncol. 17, 271-276 (2000).	<input type="checkbox"/>
46	YAMAMOTO, D. et al. "Synergistic action of apoptosis induced by eicosapentaenoic acid and TNP-470 on human breast cancer cells." Breast Cancer Res. Treatment 55, 149-160 (1999).	<input type="checkbox"/>
47	YAMAOKA, K. et al. "Overexpression of A fl-Galactoside Binding Protein Causes Transformation of Balb3T3 Fibroblast Cells." Biochem. Biophys. Res. Comm. 179(1), 272-279 (30 Aug. 1991).	<input type="checkbox"/>
48	YANG, R.-Y. et al. "Expression of galectin-3 modulates T-cell growth and apoptosis." PNAS 93, 6737-6742 (June 1996).	<input type="checkbox"/>
49	YOSHII, T. et al. "Galectin-3 Phosphorylation is Required for Its Anti-apoptotic Function and Cell Cycle Arrest." J. Biol. Chem. 277(9), 6852-6857 (1 March 2002).	<input type="checkbox"/>
50	ZENG, S. et al. "In Vitro Evaluation of Schedule-dependent Interactions between Docetaxel and Doxorubicin against Human Breast and Ovarian Cancer Cell." Clin. Cancer Res. 6, 3766-3773 (Sept. 2000).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).


☒ See attached certification statement.

☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2009-03-12
Name/Print	Barry Schindler	Registration Number	32,938

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Doc code :IDS

Doc description: Information Disclosure Statement (IDS) Filed


PTO/SB/08a (10-08)

Approved for use through 11/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930	
	Filing Date		2006-12-04	
	First Named Inventor	David Platt		
	Art Unit	1623		
	Examiner Name	Layla D. Bland		
	Attorney Docket Number	089918-021302		



U.S. PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2i</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

1	ZETTER, "Angiogenesis and tumor metastasis," Annu. Rv. Med. 49:407-424 (1998)	<input type="checkbox"/>
2	ZHU, W.-Q. et al. Rapid Release of Intracellular Galectin-3 from Breast Carcinoma Cells by Fetuin. Cancer Res. 61, 1869-1873 (1 March 2001).	<input type="checkbox"/>
3	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/557,120 dated November 20, 2007 by Examiner Patrick T. Lewis	<input type="checkbox"/>
4	Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/557,120 dated August 28, 2008 by Examiner Patrick T. Lewis	<input type="checkbox"/>
5	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/108,237 dated October 4, 2004 by Examiner James O. Wilson	<input type="checkbox"/>
6	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/649,131 dated October 4, 2004 by Examiner James O. Wilson	<input type="checkbox"/>
7	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/597,930 dated November 30, 2007 by Examiner Shaojia Anna Jiang	<input type="checkbox"/>
8	Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/597,930 dated December 23, 2008 by Examiner Layla D. Bland	<input type="checkbox"/>
9	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/649,130 dated October 4, 2004 by Examiner James O. Wilson	<input type="checkbox"/>
10	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/889,555 dated December 29, 2008 by Examiner Humera N. Sheikh	<input type="checkbox"/>
11	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 11/182,096 dated September 3 2008 by Examiner Shaojia Anna Jiang	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10597930
	Filing Date	2006-12-04
	First Named Inventor	David Platt
	Art Unit	1623
	Examiner Name	Layla D. Bland
	Attorney Docket Number	089918-021302

12	Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/657,508 dated July 18, 2008 by Examiners Eric S. Olson and Shaojia Anna Jiang	<input type="checkbox"/>
13	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/657,508 dated August 23, 2007 by Examiners Eric S. Olson and Shaojia Anna Jiang	<input type="checkbox"/>
14	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/657,508 dated October 2, 2006 by Examiner Devesh Khare	<input type="checkbox"/>
15	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 09/961,681 dated February 26 2002 by Examiner Jose G. Dees	<input type="checkbox"/>
16	Final Office Action from United States Patent and Trademark Office for U.S.S.N. 09/961,681 dated September 9 2002 by Examiner Jose G. Dees	<input type="checkbox"/>
17	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 09/818,596 dated June 2, 2003 by Examiner James O. Wilson	<input type="checkbox"/>
18	Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 09/818,596 dated December 19, 2002 by Examiner James O. Wilson	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10597930
	Filing Date	2006-12-04
	First Named Inventor	David Platt
	Art Unit	1623
	Examiner Name	Layla D. Bland
	Attorney Docket Number	089918-021302

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).


**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☒ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2009-03-12
Name/Print	Barry Schindler	Registration Number	32,938

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



Doc code :IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (10-08)

Approved for use through 11/30/2008. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

**U.S.PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6912230		2005-06-28	Salkini et al.	
	2	6936618		2005-08-23	Dormer et al.	
	3	6964761		2005-11-15	Condos et al.	
	4	6986995		2006-01-17	Rose et al.	
	5	7166299		2007-01-23	Yoo, Seo Hong	
	6	5490991		1996-02-13	Enriquez et al.	
	7	5498702		1996-03-12	Mitchell et al.	
	8	5547945		1996-08-20	Ye et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

9	5681923	1997-10-28	Platt
10	5831052	1998-11-03	Hillman et al.
11	6258383	2001-07-10	Gohlke et al.
12	6274566	2001-08-14	Eliaz et al
13	6423314	2002-07-23	Platt
14	6680306	2003-01-16	Chang et al.
15	6875451	2005-04-05	Ellison et al.

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20040091503		2004-05-13	Segal et al.	
	2	20040023925		2004-02-05	Change et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10597930
Filing Date		2006-12-04
First Named Inventor	David Platt	
Art Unit	1623	
Examiner Name	Layla D. Bland	
Attorney Docket Number	089918-021302	

	3	20040254419		2004-12-16	Wang et al.	
	4	20050154042		2005-07-04	Bratton et al.	
	5	20060057131		2006-03-16	Simard et al.	
	6	20060067927		2006-03-30	Chandrasekaran et al.	
	7	20060024357		2006-02-02	Carpenter et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2i</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	CITRO et al. "c-myc Antisense Oligodeoxynucleotides Enhance the Efficacy of Cisplatin in Melanoma Chemotherapy in Vitro and in Nude Mice." Cancer Res. 58, 283-289 (15 Jan. 1998).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

2	COMICUERET, O. "Linkingcyclins to transcriptional control." Gene 299, 35-55 (2002).	<input type="checkbox"/>
3	ELEZ, R. et al. "Tumor regression by combination antisense therapy against Plk1 and Bel-2." Oncogene 22, 69-80 (2003).	<input type="checkbox"/>
4	HERSHBERGER, P.A. "Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity in Vitro and in Vivo and Accelerates Paclitaxel-induced Apoptosis." Clin. Cancer Res. 7, 1043-1051 (April 2001).	<input type="checkbox"/>
5	IMAM et al. "Interferon-Alpha Induces bcl-2 Proto-Oncogene in Patients with Neuroendocrine Gut Tumor Responding to its Antitumor Action." Anticancer Res. 17, 4659-4666 (1997).	<input type="checkbox"/>
6	LIU et al., "Citrus Pectin: Characterization and Inhibitory Effect on Fibroblast Growth Factor - Receptor Interaction." J. Agric. Food Chem. 49:3051-3057 (2001)	<input type="checkbox"/>
7	MILLER et al. "Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Non-Small Cell Lun. Cancer." J. Clin. Oncol. 18 6 , 1346-1350 (March 2000).	<input type="checkbox"/>
8	MIZUTANI et al. "Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin." J. Urology 165, 263-270 (Jan. 2001).	<input type="checkbox"/>
9	MOHAMMAD et al. "The Addition of Bryostatins 1 to Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Chemotherapy Improves Response in a CHOP-resistant Human Diffuse Large Cell Lymphoma Xenograft Model." Clin. Cancer Res. 6, 4950-4956 (Dec. 2000).	<input type="checkbox"/>
10	SWANNIE, H. C. et al. "Protein Kinase C Inhibitors." Curr. Oncol. Reports 4(1), 37-46 (Jan. 2002).	<input type="checkbox"/>
11	TU, Y. et al., "Upregulated Expression of BCL-2 in Multiple Myeloma Cells Induced by Exposure to Doxorubicin, Etoposide, and Hydrogen peroxide Blood, Vol. 88, No 5, 1805-1812 (1996).	<input type="checkbox"/>
12	WARFIELD, P. R. "Adhesion of Human Breast Carcinoma to Extracellular Matrix Proteins Is Modulated by Galectin-3." Invasion Metastasis 17, 101-112 (1998).	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

13	APARICIO, A. "In vitro cyto-reductive effects on multiple myeloma cells induced by bisphosphonates." Leukemia 12, 220-229 (1998).	<input type="checkbox"/>
14	BALDUS, S.E. et al. "Increased Galactin-3 Expression in Gastric Cancer: Correlations with Histopathological Subtypes, Galactosylated Antigens and Tumor Cell Proliferation." Tumor Biol. 21, 258-266 (2 Jul 1999).	<input type="checkbox"/>
15	BERBERAT, P.O. et al. "Comparative Analysis of Galectins in Primary Tumors and Tumor Metastasis in Human Pancreatic Cancer." J. Histochem. Cytochem. 49, 539-549 (2001).	<input type="checkbox"/>
16	BIANCO, C. et al. "Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor." Clin. Cancer Res. 8, 3250-3258 (Oct. 2002).	<input type="checkbox"/>
17	BOLD, R.J. et al. "Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome." J. Surg. Res. 100, 11-17 (2001).	<input type="checkbox"/>
18	BREWER, C.F. "Binding and cross-linking properties of galectins. Biochim. Biophys." Acta 1572, 255-262 (2002).	<input type="checkbox"/>
19	BURKE, P.A. et al. "Combined Modality Radioimmunotherapy." Cancer 94, 1320-1331 (15 Feb. 2002).	<input type="checkbox"/>
20	CAMBY, I. et al. "Galectins are differently expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration." Brain Pathology 11, 12-26 (2001).	<input type="checkbox"/>
21	CHERAYIL, B.J. et al. "Molecular cloning of a human macrophage lectin specific for galactose." PNAS 87, 7324-7328 Sept. 1990).	<input type="checkbox"/>
22	CHOUFANI, G. et al. "The Levels of Expression of Galectin-1, Galectin-3, and the Thomsen-Friedenreich Antigen and Their Binding Sites Decrease as Clinical Aggressiveness Increases in Head and Neck Cancers. Cancer 86, 2353-2363 (1 Dec. 1999)."	<input type="checkbox"/>
23	CINDOLO, L. et al. "Galectin-1 and Galectin-3 Expression in Human Bladder Transitional-Cell Carcinomas." Int. J. Cancer 84, 39-43 (1999).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

24	COOPER, D.N.W. "Galectinomics: finding themes in complexity." Biochim Biophys Acta 1572, 209-231 (2002).	<input type="checkbox"/>
25	COQUERET, O. "Linking cyclins to transcriptional control." Gene 299, 35-55 (2002).	<input type="checkbox"/>
26	COTTER, F.E. "Controlling The Mitochondrial Gatekeeper for Effective Chemotherapy." British Journal of Haematology 111:52-60 (2000)	<input type="checkbox"/>
27	DANGUY, A. et al. "Galectins and cancer." Biochim.. Biophys Acta 1572, 285-293 (2002).	<input type="checkbox"/>
28	Definition of apoptosis and cytotoxicity, Wikipedia	<input type="checkbox"/>
29	DEL BINO, G. et al. "Altered Susceptibility of Differentiating HL-60 Cells to Apoptosis Induced by Antitumor Drugs." Leukemia 8, 281-288 (Feb. 1994).	<input type="checkbox"/>
30	DIPAOLA, R.S. and Aisner, J. "Overcoming bcl 2-and p53 Mediated Resistance in Prostate Cancer." Seminars in Oncology 26, 112-116 (Feb. 1999).	<input type="checkbox"/>
31	EASTMAN, A. and Rigas, J.R. "Modulation of Apoptosis Signaling Pathways and Cell Cycle Regulation." Seminars in Oncology 26, 7-16 (Oct. 1999).	<input type="checkbox"/>
32	FAN, W. et al. "In vitro evaluation of combination chemotherapy against human tumor cells." Oncology Reports 5, 1035-1042 (1998).	<input type="checkbox"/>
33	FRANCOIS, C. et al. "Galectin-1 and Galectin-3 Binding Pattern Expression in Renal Cell Carcinomas." Am. J. Clin. Pathol. 112, 194-203 (1999).	<input type="checkbox"/>
34	GBC 590 SafeScience Clinical Data. R&D Focus Drug News, DRUGNL. an:1186 (2001)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10597930
Filing Date	2006-12-04
First Named Inventor	David Platt
Art Unit	1623
Examiner Name	Layla D. Bland
Attorney Docket Number	089918-021302

35	GLINSKY, V.V. et al. "Effects of Thomsen-Friedenreich Antigen-specific Peptide P-30 on B-Galactoside-mediated Homotypic Aggregation and Adhesion to the Endothelium of MDA-MB 435 Human Breast Carcinoma Cells." Cancer Res. 60, 2584-2588 (15 May 2000).	<input type="checkbox"/>
36	GLINSKY, V.V. et al. "The Role of Thomsen-Friedenreich Antigen in Adhesion of Human Breast and Prostate Cancer Cells to the Endothelium." Cancer Res. 61, 4851-4857 (15 June 2001).	<input type="checkbox"/>
37	GONG, H.C. et al. "The NH2 Terminus of Galectin-3 Governs Cellular Compartmentalization and Functions in Cancer Cells." Cancer Res. 59, 6239-6245 (15 Dec. 1999).	<input type="checkbox"/>
38	GRANT, S. and Dent, P. "Rational integration of agents directed at novel therapeutic targets into combination chemotherapeutic regimens." Curr. Opin. Investigational Drugs 2, 1600-1605 (2001).	<input type="checkbox"/>
39	GROSS, A. "The role of BCL-2 family members in apoptosis." Published by the Department of Biological Regulation, Weizmann Institute of Science, Israel.	<input type="checkbox"/>
40	HARA, I. et al. "Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity." Int. J. Oncol. 17, 1213-1218 (2000).	<input type="checkbox"/>
41	HERNANDEZ, J.D. and Baum, L.G. "Ah, sweet mystery of death! Galectins and control of cell fate." Glycobiology 12, 127R-136R (2002).	<input type="checkbox"/>
42	HORTOBAGYI, G.N. "Recent Progress in the Clinical Development of Docetaxel (Taxotere)." Seminars in Oncology 26, 32-36 (June 1999).	<input type="checkbox"/>
43	HRDLICKOVA, E. et al. "Detection of galectin-3 in tear fluid at disease states and immunohistochemical and lectin histochemical analysis in human corneal and conjunctival Ophthalmol. 85, 1336-1340 (2001 ).	<input type="checkbox"/>
44	INOHARA, H. et al. "Expression of Galectin-3 in Fine-Needle Aspirates as a Diagnostic Marker Differentiating Benign from Malignant Thyroid Neoplasms." Cancer 85, 2475-2484 (1 June 1999).	<input type="checkbox"/>
45	INUFUSA, H. et al. "Role of galectin-3 in adenocarcinoma liver metastasis." Int. J. Oncol. 19, 913-919 (2001).	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10597930
	Filing Date		2006-12-04
	First Named Inventor	David Platt	
	Art Unit	1623	
	Examiner Name	Layla D. Bland	
	Attorney Docket Number	089918-021302	

	46	LURISCI, I. et al., "Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients," Clinical Cancer Research 6:1389-1393 (2000)	<input type="checkbox"/>
	47	JENSEN-JAROLIM, E. et al. "Anti-Galectin-3 IgG Autoantibodies in Patients with Crohn's Disease Characterized by Means of Phage Display Peptide Libraries." J. Clin. Immunol. 21(5), 348-356 (2001).	<input type="checkbox"/>
	48	JOHNSON, K. R. et al. "Antagonistic Interplay between Antimitotic and G1-S Arresting Agents Observed in Experimental Combination Therapy." Clin. Cancer Res. 5, 2559-2565 (Sept. 1999).	<input type="checkbox"/>
	49	JULIAO, S. et al. "Galectin-3: A Marker and Diagnostic Aid for Chordoma." Present at the 47th Annual Meeting, Orthopaedic Research Society, page 0846, February 25-28, 2001, San Francisco, CA	<input type="checkbox"/>
	50	KARMANOS, Barbara Ann Cancer Institute. "Novel Therapeutic Targets & Therapies." www.karmanos.org/we/research/prostate/novel.html retrieved on 1/27/2003.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			
<p><sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="http://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.</p>			